What started out six years ago as a local ‘passion project’ for Bayer to collaborate with Berlin’s digital health scene has grown into a truly global programme.
Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.
Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas
Bayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 million alleging that blockbuster blood thinner Xarelto caused unstoppable and someti
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.